Traders should monitor for potential dilution from the conversion of preferred stock and exercise of warrants, which could impact the share price. The small offering size suggests limited immediate capital for operations, which may raise concerns about the company's financial runway.
Price Chart
Executive Summary
Dare Bioscience completed a Regulation A offering, issuing 3,470 Investor Units at $5.00 each, with each unit consisting of one share of Series A Convertible Preferred Stock and two warrants to purchase common stock. The offering raises capital through unregistered securities sales.
Key Financial Metrics
Key Facts
- Dare Bioscience issued 3,470 Investor Units at $5.00 each, raising $17,350 in gross proceeds.
- Each Investor Unit consists of one share of Series A Convertible Preferred Stock and two warrants to purchase one share of common stock, resulting in warrants to purchase up to 6,940 shares of common stock.
- The offering is conducted under Regulation A, which allows unregistered sales up to certain limits, and was qualified by the SEC on April 1, 2026.
- The company is an emerging growth company and is using Regulation A for this offering.
Financial Impact
$17,350 raised through the issuance of 3,470 Investor Units, each priced at $5.00, with potential for additional dilution from warrant exercises.
Risk Factors
- Dilution from the conversion of Series A Convertible Preferred Stock and exercise of warrants could negatively impact existing shareholders.
- The small market cap of $27M makes the company highly sensitive to dilutive offerings, potentially leading to share price pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001401914-26-000006 |
| Document: 0001401914-26-000006-index-headers.html | 0001401914-26-000006 |
| Document: 0001401914-26-000006-index.html | 0001401914-26-000006 |
| Document: 0001401914-26-000006.txt | 0001401914-26-000006 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 19d ago | DEF 14A | $0.7900 $0.7720 | ▲ +2.28% | ▲ +1.86% | $0.6467 (+18.14%) |
Oct 1, 2026 25d ago | 8-K | $0.8510 $0.8428 | ▼ −0.96% | ▼ −1.70% | $0.6467 (−24.01%) |
Sep 9, 2026 6w ago | 8-K | $0.7166 $0.7051 | ▼ −1.60% | ▼ −1.01% | $0.6467 (−9.75%) |
Sep 4, 2026 7w ago | EFFECT | $0.7210 $0.7130 | ▲ +1.11% | ▲ +0.56% | $0.6467 (+10.31%) |
Aug 17, 2026 10w ago | 8-K | $0.8102 $0.7682 | ▲ +5.18% | ▲ +4.51% | $0.6467 (+20.18%) |
Aug 17, 2026 10w ago | 424B5 | $0.8102 $0.7682 | ▲ +5.18% | ▲ +4.51% | $0.6467 (+20.18%) |
Aug 13, 2026 10w ago | 8-K | $0.9300 $0.8102 | ▼ −12.88% | ▼ −12.41% | $0.6467 (−30.46%) |
Aug 6, 2026 11w ago | Press Release | $1.33 $1.40 | ▲ +5.26% | ▲ +4.65% | $0.6467 (−51.38%) |
Jul 24, 2026 13w ago | 8-K | $1.28 $1.32 | ▲ +3.13% | ▲ +3.10% | $0.6467 (−49.48%) |
Jul 13, 2026 15w ago | 8-K | $2.09 $2.07 | ▼ −0.96% | ▼ −1.31% | $0.6467 (−69.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers